ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

RLMD Relmada Therapeutics Inc

3.85
-0.06 (-1.53%)
After Hours
Last Updated: 16:00:01
Delayed by 15 minutes

Period:

Draw Mode:

Volume 114,585
Bid Price 3.82
Ask Price 3.90
News -
Day High 3.9603

Low
2.3601

52 Week Range

High
7.2225

Day Low 3.75
Company Name Stock Ticker Symbol Market Type
Relmada Therapeutics Inc RLMD NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.06 -1.53% 3.85 16:00:01
Open Price Low Price High Price Close Price Prev Close
3.95 3.75 3.9603 3.85 3.91
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,175 114,585 $ 3.88 $ 444,238 - 2.3601 - 7.2225
Last Trade Time Type Quantity Stock Price Currency
16:00:00 2,105 $ 3.86 USD

Relmada Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
112.87M 30.10M - 0 -98.79M -3.28 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Relmada Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No RLMD Message Board. Create One! See More Posts on RLMD Message Board See More Message Board Posts

Historical RLMD Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.624.723.704.07129,145-0.77-16.67%
1 Month4.875.093.704.51122,330-1.02-20.94%
3 Months3.917.22253.705.18218,787-0.06-1.53%
6 Months2.987.22252.4154.05234,2530.8729.19%
1 Year2.627.22252.36013.55203,5801.2346.95%
3 Years37.0140.001.8112.24321,194-33.16-89.60%
5 Years10.8554.001.8116.82256,016-7.00-64.52%

Relmada Therapeutics Description

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Your Recent History

Delayed Upgrade Clock